HEALTHJun 8 · 11:55 UTCSTAT NEWSAndrew Joseph

STAT+: Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate

A combination of Tango Therapeutics' vopimetostat and Revolution Medicines' daraxonrasib showed durable responses in most pancreatic cancer patients in an early-stage trial. Revolution's drug has demonstrated unprecedented outcomes, highlighting potential in oncology treatments.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

Tango TherapeuticsorganizationRevolution Medicinesorganizationvopimetostattopicdaraxonrasibtopicpancreatic cancertopiconcologytopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

HEALTHJun 4 · 10:30 UTC
STAT+: Does Revolution Medicines’ pancreatic cancer drug have even greater potential?
HEALTHMay 1 · 19:14 UTC
FDA expands access to drug helping pancreatic cancer patients
HEALTHMay 31 · 12:00 UTC
STAT+: Practice-changing results reported for Revolution Medicines pancreatic cancer drug
HEALTHMay 29 · 18:00 UTC
Patients, doctors hail 'revolutionary' new drug for pancreatic cancer
HEALTHMay 31 · 12:07 UTC
Experimental pill promises new hope for deadly pancreatic cancer
HEALTHMay 31 · 15:08 UTC
New drug nearly doubles survival rates in some pancreatic cancer patients, study says